JP2002533335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002533335A5 JP2002533335A5 JP2000589530A JP2000589530A JP2002533335A5 JP 2002533335 A5 JP2002533335 A5 JP 2002533335A5 JP 2000589530 A JP2000589530 A JP 2000589530A JP 2000589530 A JP2000589530 A JP 2000589530A JP 2002533335 A5 JP2002533335 A5 JP 2002533335A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- tumor cells
- aryl
- ring
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 27
- 210000004881 tumor cell Anatomy 0.000 description 26
- 125000000217 alkyl group Chemical group 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 14
- 125000003710 aryl alkyl group Chemical group 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- -1 benzotriazol-1-yloxy, tetrazol-5-ylthio Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N C[n]1cncc1 Chemical compound C[n]1cncc1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21656098A | 1998-12-18 | 1998-12-18 | |
| US09/216,560 | 1998-12-18 | ||
| PCT/US1999/027938 WO2000037458A1 (en) | 1998-12-18 | 1999-12-16 | Farnesyl protein transferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002533335A JP2002533335A (ja) | 2002-10-08 |
| JP2002533335A5 true JP2002533335A5 (https=) | 2007-02-08 |
Family
ID=22807539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000589530A Pending JP2002533335A (ja) | 1998-12-18 | 1999-12-16 | ファルネシルタンパク質トランスフェラーゼインヒビター |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1140904B1 (https=) |
| JP (1) | JP2002533335A (https=) |
| KR (1) | KR20010081115A (https=) |
| CN (1) | CN1285588C (https=) |
| AR (1) | AR021716A1 (https=) |
| AT (1) | ATE293622T1 (https=) |
| AU (1) | AU2347900A (https=) |
| BR (1) | BR9916328A (https=) |
| CA (1) | CA2354774C (https=) |
| CO (1) | CO5160344A1 (https=) |
| CZ (1) | CZ20011900A3 (https=) |
| DE (1) | DE69924876T2 (https=) |
| ES (1) | ES2237963T3 (https=) |
| HU (1) | HUP0203054A3 (https=) |
| ID (1) | ID29065A (https=) |
| IL (1) | IL143409A0 (https=) |
| NO (1) | NO20012960L (https=) |
| PE (1) | PE20001516A1 (https=) |
| PL (1) | PL348294A1 (https=) |
| SK (1) | SK7582001A3 (https=) |
| TR (1) | TR200101754T2 (https=) |
| WO (1) | WO2000037458A1 (https=) |
| ZA (1) | ZA200104236B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034567A1 (en) * | 1999-11-10 | 2001-05-17 | Aventis Pharma Deutschland Gmbh | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa |
| US7361663B2 (en) | 1999-11-10 | 2008-04-22 | Aventis Pharmaceuticals Inc. | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa |
| US6589978B2 (en) * | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| US6809093B2 (en) | 2000-10-17 | 2004-10-26 | H. Lee Moffitt Cancer & Research Institute, Inc. | 2-substituted heterocyclic compounds |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
| AU2002236813A1 (en) | 2001-01-22 | 2002-07-30 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| ATE455108T1 (de) | 2001-02-16 | 2010-01-15 | Aventis Pharma Inc | Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden |
| AU2002257114A1 (en) * | 2001-04-06 | 2002-10-21 | Schering Corporation | Treatment of malaria with farsenyl protein transferase inhibitors |
| FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| US6740757B2 (en) * | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2844273B1 (fr) | 2002-09-05 | 2008-04-04 | Aventis Pharma Sa | Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens. |
| MXPA05006485A (es) * | 2002-12-17 | 2005-08-26 | Schering Corp | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno. |
| MX2007007074A (es) | 2004-12-13 | 2007-09-04 | Schering Corp | Inhibidores novedosos de proteina transferasa de farnesilo y su uso para tratar cancer. |
| CA2591123A1 (en) | 2004-12-14 | 2006-06-22 | Schering Corporation | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases |
| CA2637572A1 (en) * | 2006-01-19 | 2007-07-26 | Schering Corporation | Piperazine derivatives as farnesyl protein transferase inhibitors |
| WO2009143033A1 (en) * | 2008-05-22 | 2009-11-26 | Merck & Co., Inc. | Process for the preparation of an orexin receptor antagonist |
| HU231150B1 (hu) | 2017-03-13 | 2021-03-29 | Richter Gedeon Nyrt | Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására |
| CN114286675A (zh) | 2019-06-04 | 2022-04-05 | 海格生物科学有限责任公司 | 作为食欲肽拮抗剂的咪唑衍生物、组合物以及方法 |
| TWI907472B (zh) | 2020-08-05 | 2025-12-11 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
| CN114349711B (zh) * | 2022-02-28 | 2023-08-15 | 四川依维欣医药科技有限公司 | 一种（R）-1-Boc-3-羟甲基哌嗪的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| GB9420172D0 (en) * | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| HUP0003138A3 (en) * | 1997-06-17 | 2002-11-28 | Schering Corp | Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase |
-
1999
- 1999-12-16 TR TR2001/01754T patent/TR200101754T2/xx unknown
- 1999-12-16 EP EP99967139A patent/EP1140904B1/en not_active Expired - Lifetime
- 1999-12-16 CZ CZ20011900A patent/CZ20011900A3/cs unknown
- 1999-12-16 PL PL99348294A patent/PL348294A1/xx not_active Application Discontinuation
- 1999-12-16 HU HU0203054A patent/HUP0203054A3/hu unknown
- 1999-12-16 CA CA002354774A patent/CA2354774C/en not_active Expired - Fee Related
- 1999-12-16 AT AT99967139T patent/ATE293622T1/de not_active IP Right Cessation
- 1999-12-16 AR ARP990106459A patent/AR021716A1/es unknown
- 1999-12-16 IL IL14340999A patent/IL143409A0/xx unknown
- 1999-12-16 WO PCT/US1999/027938 patent/WO2000037458A1/en not_active Ceased
- 1999-12-16 ID IDW00200101310A patent/ID29065A/id unknown
- 1999-12-16 ES ES99967139T patent/ES2237963T3/es not_active Expired - Lifetime
- 1999-12-16 BR BR9916328-4A patent/BR9916328A/pt not_active IP Right Cessation
- 1999-12-16 SK SK758-2001A patent/SK7582001A3/sk unknown
- 1999-12-16 CO CO99078838A patent/CO5160344A1/es unknown
- 1999-12-16 DE DE69924876T patent/DE69924876T2/de not_active Expired - Fee Related
- 1999-12-16 JP JP2000589530A patent/JP2002533335A/ja active Pending
- 1999-12-16 KR KR1020017007535A patent/KR20010081115A/ko not_active Withdrawn
- 1999-12-16 AU AU23479/00A patent/AU2347900A/en not_active Abandoned
- 1999-12-16 CN CNB998162078A patent/CN1285588C/zh not_active Expired - Fee Related
- 1999-12-17 PE PE1999001293A patent/PE20001516A1/es not_active Application Discontinuation
-
2001
- 2001-05-23 ZA ZA200104236A patent/ZA200104236B/en unknown
- 2001-06-15 NO NO20012960A patent/NO20012960L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002533335A5 (https=) | ||
| EP3277276B1 (en) | Methods of administering glutaminase inhibitors | |
| CA2960876C (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
| KR920700200A (ko) | 19-노르-비타민 d 화합물 | |
| JP2016510748A (ja) | 癌の処置のための組成物 | |
| CN111170991A (zh) | 抗增殖化合物及其合成方法 | |
| JP2019048850A (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| US9682082B2 (en) | Combinations of AKT and MEK inhibitor compounds, and methods of use | |
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| KR102748684B1 (ko) | 술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법 | |
| US20180250261A1 (en) | Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor | |
| CN115397820A (zh) | 用于治疗骨髓增生性肿瘤的赖氨酸特异性组蛋白脱甲基化酶抑制剂 | |
| US20210380547A1 (en) | Urea derivatives for treating and/or preventing cancer | |
| RU2004111787A (ru) | Ретиноидные агонисты (1), производные алкилмочевины | |
| RU98119949A (ru) | АНТАГОНИСТЫ α-АДРЕНЭРГИЧЕСКОГО РЕЦЕПТОРА | |
| RU2001124601A (ru) | Фенилаланиловые производные | |
| KR20190111035A (ko) | 퀴놀린 유도체의 에탄술폰산염 | |
| JP2008545803A5 (https=) | ||
| JP2002533336A5 (https=) | ||
| JP2026500719A (ja) | アルファ－ｖ－ベータ－８インテグリン阻害剤及びその使用 | |
| JP2026510946A (ja) | レチンアルデヒドデヒドロゲナーゼ１（ｒａｌｄｈ１）阻害剤および免疫賦活剤の組み合わせならびにそれらの使用方法 | |
| KR20000075769A (ko) | 디아미노트리플루오로메틸피리딘 유도체를 포함하는 항암 조성물 | |
| JPWO2021127217A5 (https=) | ||
| WO2018113758A1 (zh) | 一种作为吲哚胺-2，3-双加氧酶抑制剂的砜脒及其制备方法和用途 |